Eli Lilly and Company (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively. Earnings estimates for 2024 have declined from $16.47 to $13.83 per share over the past 30 days. The decline in estimates could be due to costs related to the acquisition of Morphic, which was closed in August and should be recorded as a charge against earnings in the third quarter.  For 2025 ...